EUCTR2015-002915-14-IT进行中（未招募）1 期
A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton's TyrosineKinase (BTK) Inhibitor. - COSMOS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- MORPHOSYS AG
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age =18 years
- •2. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma(SLL):
- •a) history of diagnosis of CLL or SLL that meets IWCLL diagnostic criteria
- •b) histologically confirmed diagnosis of SLL by lymph node biopsy and documented within medical records
- •c) indication for treatment as defined by the IWCLL guidelines
- •3. Patients must have both of the following:
- •a) relapsed (1) or refractory (2) disease while receiving a BTK inhibitor (e.g., ibrutinib) or intolerance of such therapy
- •b) single-agent or combination therapy with a BTK inhibitor for at least one month must be the patient's most recent prior anticancer therapy
- •(1) relapsed disease is defined as progressive disease in subjects who have previously achieved a PR or CR to most recent BTK inhibitor therapy
- •(2) refractory disease is defined as progressive disease in subjects who have previously not achieved a PR or CR to most recent BTK inhibitor
- •therapy, or stable disease as best response after 12 months of receiving the most recent BTK inhibitor therapy
- •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •5. Patients with a past medical history of autologous or allogeneic stem cell transplantation must exhibit full hematological recovery without any evidence of active graft versus host disease before enrolment into the study.
- •Laboratory Values
- •6. Patients must meet the following laboratory criteria at screening:
- •adequate bone marrow function as follows:
- •a) absolute neutrophil count (ANC) = 1.0 × 109/L
- •b) platelet count = 30 × 109/L in the absence of clinically significant evidence of bleeding
- •Adequate hepatic and renal function as follows:
- •c) total serum bilirubin = 1.5 × ULN or = 3 × ULN in cases of
- •documented liver involvement by CLL (For patients with Gilbert's disease, serum bilirubin up to 3 × ULN is allowed provided normal direct bilirubin.)
- •d) ALT and AST = 2.5 × ULN or <3 ×ULN in cases of documented liver involvement by CLL
- •e) serum creatinine clearance must be = 30 mL/min calculated using a standard Cockcroft-Gault formula (Cockroft & Gault, 1976)
- •Other Inclusion Criteria
- •7. Females of childbearing potential (FCBP; see Appendix F of the protocol) must:
- •a) not be pregnant as confirmed by a negative serum pregnancy test at screening and a urine pregnancy test prior to starting study therapy
- •b) refrain from breastfeeding and donating blood or oocytes during the
- •course of the study and for 3 months after the last dose of study medication (Note: All female patients are prohibited to donate blood within the before mentioned time frame)
- •c) agree to ongoing pregnancy testing during the course of the study, and until 3 months after study therapy has ended. This applies even if the patient practices complete and continued sexual abstinence
- •d) commit to continued abstinence from heterosexual intercourse if it is
- •in accordance with her lifestyle or agree to use and be able to comply with the use of highly effective contraception (see Appendix F of the protocol) without interruption during the study and for 3 months after the last dose of study medication
- •e) FCBP using hormonal contraceptives should add a barrier method as a second form of contraception since it is currently unknown whether idelalisib may affect the effectiveness of hormonal contraceptives
- •8. Males must use a highly effective method of contraception (see Appendix F of the protocol) without interruption, if the patient is sexually active with a FCBP, refrain from donating blood
排除标准
- •1. Patients who have:
- •a) non-Hodgkin's lymphomas other than CLL/SLL
- •b) transformed CLL/SLL or Richter's syndrome as defined by the IWCLL
- •c) active and uncontrolled autoimmune cytopenia
- •Previous and Current Treatment
- •2. Patients who have received treatment with a BTK inhibitor within 5 days prior to Day 1 dosing.
- •3. Patients who have, within 14 days prior to Day 1 dosing:
- •a) not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy
- •b) systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day
- •c) received live vaccines. (Note: Vaccinations against influenza with inactivated virus or vaccination for pneumococcal diseases are allowed.)
- •4. Patients who:
- •a) have, in the opinion of the Investigator, not recovered sufficiently from the adverse toxic effects of prior therapies
- •b) were previously treated with CD19-targeted therapy or a PI3K inhibitor treatment (e.g., idelalisib, duvelisib)
- •c) have a history of previous severe allergic reactions to prior monoclonal antibody therapy, and/or hypersensitivity to the active substances or to any of the inactive ingredients / excipients contained in the study drug formulations (for details see FDA Prescribing Information or EMA SmPC of Zydelig®)
- •d) concurrently use other anticancer or experimental treatments Patient's Medical History
- •5. Prior history of malignancies other than CLL, unless the patient has been free of the disease for =5 years prior to screening. Exceptions to the =5 year time limit include a history of the following:
- •a) basal cell carcinoma of the skin
- •b) squamous cell carcinoma of the skin
- •c) carcinoma in situ of the cervix
- •d) carcinoma in situ of the breast
- •e) carcinoma in situ of the bladder
- •f) incidental histological finding of prostate cancer
- •(Tumor/Nodes/Metastasis [TNM] stage of T1a orT1b)
- •6. Patients with myelodysplastic syndrome
- •7. Patients with systemic diseases (e.g., cardiovascular, renal, hepatic) that would in the Investigator's opinion preclude participation in the
- •study or compromise the patient's ability to give informed consent
- •8. Patients with diagnosis of myocardial infarction within 6 months prior to enrolment, New York Heart Association (NYHA; see Appendix G of the protocol) class II or higher congestive heart failure, uncontrolled angina pectoris, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities, in the opinion of the Investigator. (Note: Patients with stable, asymptomatic atrial fibrillation are allowed in the study provided they do not meet the other cardiac exclusion criteria)
- •9. Patients who:
- •a) suffered significant traumatic injury or underwent major surgery within 14 days prior to treatment start
- •b) have not recovered from sequelae of traumatic injury or surgical operations until Day 1 dosing
- •10. Patients with central nervous system (CNS) involvement or impairment:
- •a) CNS primary or secondary malignancy in present or past medical history (unless patient has been free of the disease for = 5 years prior to screening) (1)
- •b) CNS, meningeal or epidural malignancies (e.g., brain metastases, known leukemic meningeosis) (1)
- •(1) Note: Screening for cerebrospinal fluid (CSF)/CNS involvement is not required but may be performed at the discretion of the Investigator
- •c) CNS lesions/cerebrovascular event(s) with clinically significan
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of MOR00208 used in combination with Idelalisib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma who have been previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor.Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaMedDRA version: 18.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 100000004864EUCTR2015-002915-14-FRMorphoSys AG120
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromesEUCTR2020-003400-13-FRGroupe Francophone des Myélodysplasies (GFM)40
进行中（未招募）
1 期
Clinical study to evaluate the safety and effectiveness of lenalidomide combined with MOR00208 in adult patients with diffuse large B cell lymphoma that has progressed after previous treatmentEUCTR2014-004688-19-DEMorphoSys AG80
进行中（未招募）
1 期
Clinical study to evaluate the safety and effectiveness of lenalidomide combined with MOR00208 in adult patients with diffuse large B cell lymphoma that has progressed after previous treatmentEUCTR2014-004688-19-BEMorphoSys AG80
进行中（未招募）
1 期
Clinical study to evaluate the safety and effectiveness of lenalidomide combined with MOR00208 in adult patients with diffuse large B cell lymphoma that has progressed after previous treatmentRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)MedDRA version: 18.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004688-19-FRMorphoSys AG80